Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05501704 · ClinicalTrials.gov registry record · Phase 2

ETHAN - ET for Male BC

A Phase 2 study of Hormone Receptor-Positive Breast Cancer and Male Breast Cancer, sponsored by Jose Pablo Leone.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
8
Study locations

NCT05501704 is a Phase 2 study of Hormone Receptor-Positive Breast Cancer and Male Breast Cancer that is actively recruiting participants, run by Jose Pablo Leone. The registered enrollment target is 60 participants, below the 186-participant average among 23 other Hormone Receptor-Positive Breast Cancer trials with a reported enrollment target (68% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05501704, a Phase 2 study of Hormone Receptor-Positive Breast Cancer and Male Breast Cancer, is actively recruiting participants, sponsored by Jose Pablo Leone.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
8
Study locations

Study Summary

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib

Conditions Studied

Hormone Receptor-Positive Breast Cancer Male Breast Cancer Hormone Receptor-Negative Breast Carcinoma

Interventions

  • DRUG Tamoxifen
  • DRUG Anastrozole
  • DRUG Abemaciclib
  • DRUG Degarelix

Study Locations (8)

Pennsylvania

  • University of Pennsylvania, Abramson Cancer Center - Philadelphia
  • University of Pittsburgh Cancer Institute - Pittsburgh

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic - Rochester

North Carolina

  • UNC Lineberger Comprehensive Cancer Center - Chapel Hill

Tennessee

  • Vanderbilt Cancer Center - Nashville

Texas

  • M. D. Anderson Cancer Center at University of Texas - Houston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-10-11
Est. Completion 2036-04-01
Phase Phase 2

Sponsor

Jose Pablo Leone

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05501704

The ClinicalTrials.gov registry entry for NCT05501704 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 23 other Hormone Receptor-Positive Breast Cancer trials with a reported enrollment target (68% lower). The listed sponsor is Jose Pablo Leone, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hormone Receptor-Positive Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Tamoxifen is the first listed.

NCT05501704 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Pennsylvania, District of Columbia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05501704 about?

NCT05501704 is a clinical study titled "ETHAN - ET for Male BC". This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemacic...

What is the current status of trial NCT05501704?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-10-11. Estimated completion is 2036-04-01.

What conditions does trial NCT05501704 study?

This clinical trial studies the following conditions: Hormone Receptor-Positive Breast Cancer, Male Breast Cancer, Hormone Receptor-Negative Breast Carcinoma.

What interventions are being tested in trial NCT05501704?

The interventions under investigation include: Tamoxifen (DRUG), Anastrozole (DRUG), Abemaciclib (DRUG), Degarelix (DRUG).

Who is sponsoring clinical trial NCT05501704?

This trial is sponsored by Jose Pablo Leone, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05501704 being conducted?

This trial has 8 study locations across District of Columbia, Massachusetts, Minnesota, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hormone Receptor-Positive Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hormone Receptor-Positive Breast Cancer

All registered trials for this condition

Male Breast Cancer

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.